CSL-Ltd-CSLAX-Deep-dive-into-Pipeline-A12-to-Target-Price.pdf
This is a recently released Goldman Sachs report detailing the current R&D landscape for CSL. It provides the rational behind their $312 target price. Of course, with all broker reports you have to take them with a grain of salt. However, they explore each of the 15 projects in/near active development, assessing the data and the likely regulatory pathway and financial impact. Awesome read for anyone wanted a breakdown of the underlying molecules, the target markets and the overall opportunities. I feel sorry for the intern Riashad Monjur, who gets a brief shoutout for probably writing the whole thing. As usual DYOR.
Goldman Sachs R&D Report
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.64 |
Change
-0.840(0.29%) |
Mkt cap ! $142.1B | |||
| Open | High | Low | Value | Volume |
| $295.00 | $295.81 | $292.75 | $491.5M | 1.668M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 254 | $293.64 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $293.66 | 138 | 1 |
View Market Depth
| Last trade - 16.10pm 20/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |